Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925867 | 0.89 | — | — | |
| SCHEMBL31753982 | 0.86 | EGFR (0.36) | EGFR | |
| SCHEMBL22366961 | 0.85 | EGFR (0.40) | EGFRHTR2AHTR2C | |
| SCHEMBL22323620 | 0.82 | EGFR (0.43) | EGFRHTR2AHTR2C | |
| SCHEMBL29447049 | 0.82 | EGFR (0.43) | EGFRHTR2AHTR2C | |
| SCHEMBL29276144 | 0.78 | LIPE (0.36) | EGFR | |
| SCHEMBL30994355 | 0.78 | — | — | |
| SCHEMBL16035665 | 0.77 | LPL (0.35) | — | |
| SCHEMBL29556343 | 0.77 | LPL (0.35) | — | |
| SCHEMBL22324244 | 0.77 | EGFR (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | EGFR 4725/4885HTR2A 493/4885HTR2C 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.